Cannabinoid signaling and liver therapeutics

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 891-896

  Mallat, Ariane ^a,b   Teixeira Clerc, Fatima ^a,b   Lotersztajn, Sophie ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

CB1 CB2 Endocannabinoid system Fatty liver disease Fibrosis Steatosis Liver regeneration Kupffer cells Inflammation

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID RECEPTOR; ENDOCANNABINOID; RIMONABANT;

ALCOHOL LIVER DISEASE; ALCOHOLISM; APOPTOSIS; ARTICLE; CHRONIC LIVER DISEASE; DISEASE COURSE; FIBROGENESIS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; LIVER REGENERATION; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PRIORITY JOURNAL;

CB1; CB2; ENDOCANNABINOID SYSTEM; FATTY LIVER DISEASE; FIBROSIS; INFLAMMATION.; KUPFFER CELLS; LIVER REGENERATION; STEATOSIS;

ANIMALS; APOPTOSIS; ENDOCANNABINOIDS; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; LIVER DISEASES; LIVER DISEASES, ALCOHOLIC; LIVER REGENERATION; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION;

EID: 84884413612     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.03.032     Document Type: Note

References (29)

1. A. Mallat, F. Teixeira-Clerc, V. Deveaux, S. Manin, and S. Lotersztajn The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings Br J Pharmacol 163 2011 1432 1440
2. S. Lotersztajn, F. Teixeira-Clerc, B. Julien, V. Deveaux, Y. Ichigotani, and S. Manin CB2 receptors as new therapeutic targets during liver diseases Br J Pharmacol 153 2008 286 289
3. I. Matias, and V. Di Marzo Endocannabinoids and the control of energy balance Trends Endocrinol Metab 18 2007 27 37 (Pubitemid 44960014)
4. D. Osei-Hyiaman, J. Liu, L. Zhou, G. Godlewski, J. Harvey-White, and W.I. Jeong Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice J Clin Invest 118 2008 3160 3169
5. J. Tam, V.K. Vemuri, J. Liu, S. Batkai, B. Mukhopadhyay, and G. Godlewski Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J Clin Invest 120 2010 2953 2966
6. M. Gary-Bobo, G. Elachouri, J.F. Gallas, P. Janiak, P. Marini, and C. Ravinet-Trillou Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats Hepatology 46 2007 122 129 (Pubitemid 47171928)
7. T. Jourdan, L. Demizieux, J. Gresti, L. Djaouti, L. Gaba, and B. Verges Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: evidence from cultured explants Hepatology 55 2012 790 799
8. T. Jourdan, L. Djaouti, L. Demizieux, J. Gresti, B. Verges, and P. Degrace CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice Diabetes 59 2010 926 934
9. D. Chanda, D.K. Kim, T. Li, Y.H. Kim, S.H. Koo, and C.H. Lee Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes J Biol Chem 286 2011 27971 27979
10. G.G. Muccioli, D. Naslain, F. Backhed, C.S. Reigstad, D.M. Lambert, and N.M. Delzenne The endocannabinoid system links gut microbiota to adipogenesis Mol Syst Biol 6 2010 392
11. W.I. Jeong, D. Osei-Hyiaman, O. Park, J. Liu, S. Batkai, and P. Mukhopadhyay Paracrine activation of hepatic CB(1) receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver Cell Metab 7 2008 227 235 (Pubitemid 351285525)
12. F. Teixeira-Clerc, B. Julien, P. Grenard, J. Tran-Van-Nhieu, V. Deveaux, and V. Serriere-Lanneau CB1 cannabinoid receptor antagonism: a novel strategy for the treatment of liver fibrosis Nat Med 12 2006 671 676 (Pubitemid 43865236)
13. L.D. DeLeve, X. Wang, G.C. Kanel, R.D. Atkinson, and R.S. McCuskey Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis Am J Pathol 173 2008 993 1001
14. F.A. Giannone, M. Baldassarre, M. Domenicali, G. Zaccherini, F. Trevisani, and M. Bernardi Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis Lab Invest 92 2012 384 395
15. B. Mukhopadhyay, R. Cinar, S. Yin, J. Liu, J. Tam, and G. Godlewski Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver Proc Natl Acad Sci U S A 108 2011 6323 6328
16. L. Moezi, S.A. Gaskari, and S.S. Lee Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis Am J Physiol Gastrointest Liver Physiol 295 2008 G649 G653
17. A. Louvet, F. Teixeira-Clerc, M.N. Chobert, V. Deveaux, C. Pavoine, and A. Zimmer Cannabinoid CB2 receptors protect against alcoholic liver disease by regulating Kupffer cell polarization in mice Hepatology 54 2011 1217 1226
18. V. Deveaux, T. Cadoudal, Y. Ichigotani, F. Teixeira-Clerc, A. Louvet, and S. Manin Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis PLoS One 4 2009 e5844
19. Z. Cao, M.M. Mulvihill, P. Mukhopadhyay, H. Xu, K. Erdelyi, and E. Hao Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice Gastroenterology 144 2013 808 817
20. F. Teixeira-Clerc, M.P. Belot, S. Manin, V. Deveaux, T. Cadoudal, and M.N. Chobert Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration Hepatology 52 2010 1046 1059
21. D. Vara, M. Salazar, N. Olea-Herrero, M. Guzman, G. Velasco, and I. Diaz-Laviada Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy Cell Death Differ 18 2011 1099 1111
22. B. Julien, P. Grenard, F. Teixeira-Clerc, J. Tran-Van-Nhieu, L. Li, and M. Karzak Antifibrogenic role of the cannabinoid receptor CB2 in the liver Gastroenterology 128 2005 742 755 (Pubitemid 40585376)
23. J. Munoz-Luque, J. Ros, G. Fernandez-Varo, S. Tugues, M. Morales-Ruiz, and C.E. Alvarez Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats J Pharmacol Exp Ther 324 2008 475 483 (Pubitemid 351185849)
24. F. Lafdil, A. Guillot, A. Bizy, K. Zoltani, V. Deveaux, and S. Zafrani Inhibition of the pro-fibrogenic Th17 immune response by cannabinoid receptor 2 agonist decreases liver fibrosis J Hepatol 56 2012 S152-S152
25. C. Hezode, F. Roudot-Thoraval, S. Nguyen, P. Grenard, B. Julien, and E.S. Zafrani Daily cannabis smoking as a risk factor for fibrosis progression in chronic hepatitis C Hepatology 42 2005 63 71 (Pubitemid 40911312)
26. C. Hezode, E.S. Zafrani, F. Roudot-Thoraval, C. Costentin, A. Hessami, and M. Bouvier-Alias Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C Gastroenterology 134 2008 432 439 (Pubitemid 351173051)
27. L.F. Van Gaal, A.J. Scheen, A.M. Rissanen, S. Rossner, C. Hanotin, and O. Ziegler Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study Eur Heart J 29 2008 1761 1771 (Pubitemid 352019811)
28. J.P. Despres, R. Ross, G. Boka, N. Almeras, and I. Lemieux Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial Arterioscler Thromb Vasc Biol 29 2009 416 423
29. J. Tam, R. Cinar, J. Liu, G. Godlewski, D. Wesley, and T. Jourdan Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance Cell Metab 16 2012 167 179